AI Robotics in Medicine
PublicTracking updates in AI Robotics in the healthcare industry
Flok Health raises $12.5M; AI care models scrutinized
Monday, Jun 8, 2026
AI-driven care platforms are accelerating from both private and public angles: Flok Health secured $12.
5M to scale what it says is Europe’s first approved fully autonomous, end-to-end patient delivery platform with NHS-partnership results, while Tempus AI blends a multimodal data platform with diagnostics labs and AI tools, reporting about $1.
36B in U.S. medical labs and research revenue plus FDA-cleared companion diagnostics and new launches.
The tension is momentum versus sustainability: the Tempus screener flags continuing losses, funding and reimbursement risks, and a valuation with high expectations—so watch whether regulatory approvals and real-world outcomes translate into durable markets as Flok expands and Tempus broadens its offerings.
Tracking: Medicine Robotics · AI Medicine · AI Healthcare
Geography: United States, European Union, United Kingdom, China, Japan, South Korea, Israel, Singapore, India, Canada, Australia, Boston, San Francisco Bay Area, Silicon Valley, London, Cambridge (UK), Toronto, Montreal, Tel Aviv, Beijing, Shanghai, Shenzhen
1. Flok Health raises $12.5M as AI care platforms gain momentum
UK-based Flok Health raised a $12. 5 million Series A led by AlbionVC, with Mercia Ventures and existing backers Eka Ventures and Form Ventures participating.
The company says its platform is Europe’s first approved for fully autonomous, end-to-end healthcare delivery direct to patients and reports results across NHS partnerships.
Funding will scale existing services and support expansion into new clinical domains and markets.
In public markets, a Simply Wall Street screener highlights Tempus AI’s model of combining a multimodal data platform, diagnostics labs, and AI tools for oncology and genetic care. Tempus reports about $1.
36 billion in U.S. medical labs and research revenue, alongside FDA-cleared companion diagnostics and new launches in whole-genome sequencing, digital pathology, and agentic AI.
The analysis also flags continuing losses, funding and reimbursement risks, and a valuation that bakes in high expectations.
Key facts:
- Flok Health raised $12.5 million Series A led by AlbionVC.
- Mercia Ventures, Eka Ventures, and Form Ventures participated.
- Flok says it is Europe's first approved fully autonomous end-to-end AI care platform.
- Flok reports results across NHS partnerships and plans expansion.
- Tempus AI reports about $1.36 billion U.S. medical labs and research revenue.
Why it matters: Capital is flowing to divergent AI healthcare plays: autonomous care delivery (Flok) and data‑driven diagnostics (Tempus). If Flok’s claimed ‘autonomous’ model scales safely with NHS partners, it could expand capacity without proportional clinical staffing.
Tempus shows how AI tied to labs, regulated diagnostics, and pharma partnerships can embed in care pathways—but profitability and reimbursement remain hurdles.
Watch for independent clinical validation, post‑deployment performance with health systems, and payer responses to AI‑enabled services, which will shape adoption and returns.